| Literature DB >> 36010928 |
Hyein Ahn1, Geum Jong Song2, Si-Hyong Jang1, Hyun Ju Lee1, Moon-Soo Lee2, Ji-Hye Lee1, Mee-Hye Oh1, Geum Cheol Jeong3, Sang Mi Lee3, Jeong Won Lee4.
Abstract
The relationship between 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron emission tomography/computed tomography (PET/CT) textural features and histopathological findings in gastric cancer has not been fully evaluated. We investigated the relationship between the textural features of primary tumors on FDG PET/CT with histopathological findings and recurrence-free survival (RFS) in patients with advanced gastric cancer (AGC). Fifty-six patients with AGC who underwent FDG PET/CT for staging work-ups were retrospectively enrolled. Conventional parameters and the first- and second-order textural features of AGC were extracted using PET textural analysis. Upon histopathological analysis, along with histopathological classification and staging, the degree of CD4, CD8, and CD163 cell infiltrations and expressions of interleukin-6 and matrix-metalloproteinase-11 (MMP-11) in the primary tumor were assessed. The histopathological classification, Lauren classification, lymph node metastasis, CD8 T lymphocyte and CD163 macrophage infiltrations, and MMP-11 expression were significantly associated with the textural features of AGC. The multivariate survival analysis showed that increased FDG uptake and intra-tumoral metabolic heterogeneity were significantly associated with an increased risk of recurrence after curative surgery. Textural features of AGC on FDG PET/CT showed significant correlations with the inflammatory response in the tumor microenvironment and histopathological features of AGC, and they showed significant prognostic values for predicting RFS.Entities:
Keywords: F-18 fluorodeoxyglucose; positron emission tomography; prognosis; textural feature
Year: 2022 PMID: 36010928 PMCID: PMC9406203 DOI: 10.3390/cancers14163936
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Maximal intensity projection image (a) and transaxial PET (b), CT (c), and fused PET/CT (d,e) images of FDG PET/CT showing an example of VOI for extracting textural features of gastric cancer. A 76-year-old man underwent FDG PET/CT for staging work-up of gastric cancer in the stomach antrum. The cancer lesion was histopathologically classified as tubular adenocarcinoma, the intestinal type, and showed intensely increased FDG uptake on PET/CT images with a maximum SUV of 8.28 (arrows on (a,b,d)). A VOI was manually drawn around the gastric cancer lesion, and an area that showed a higher SUV than the threshold SUV of 3.45 determined by the modified Nestle’s adaptive threshold method was automatically selected within the VOI (blue color area in (e)). The PET/CT textural features of the gastric cancer lesion were extracted from this area.
Figure 2Representative images of immunohistochemical staining of CD4 ((a,f), ×200), CD8 ((b,g), ×200), CD163 ((c,h), ×200), MMP-11 ((d,i), ×200), and IL-6 ((e,j), ×200) in the tumor tissue. Examples of a score range of 0-1 are shown in (a–e), and examples of a score range of 2–3 are shown in (f–j).
Clinical characteristics of the study population (n = 56).
| Variables | Number of Patients (%) | |
|---|---|---|
| Age (years) | Median 59 (range, 34–80) | |
| Sex | Men | 35 (62.5%) |
| Women | 21 (37.5%) | |
| Body mass index (kg/m2) | Median 22.6 (range, 16.4–31.5) | |
| Tumor location | Upper | 4 (7.1%) |
| Middle | 23 (41.1%) | |
| Lower | 29 (51.8%) | |
| Histopathological classification | Papillary/tubular adenocarcinoma | 34 (60.7%) |
| Poorly-differentiated adenocarcinoma | 14 (25.0%) | |
| Signet ring cell carcinoma | 8 (14.3%) | |
| Lauren classification | Intestinal | 21 (37.5%) |
| Non-intestinal | 35 (62.5%) | |
| pT stage | T2 stage | 14 (25.0%) |
| T3 stage | 21 (37.5%) | |
| T4 stage | 21 (37.5%) | |
| pN stage | N0 stage | 18 (32.1%) |
| N1–N3 stage | 38 (67.9%) | |
| TNM stage | Stage I | 8 (14.3%) |
| Stage II | 16 (28.6%) | |
| Stage III | 32 (57.1%) | |
| CD4 cell infiltration | Grade 0 | 14 (25.0%) |
| Grade 1 | 18 (32.1%) | |
| Grade 2 | 15 (26.8%) | |
| Grade 3 | 9 (16.1%) | |
| CD8 cell infiltration | Grade 0 | 10 (17.9%) |
| Grade 1 | 11 (19.6%) | |
| Grade 2 | 19 (33.9%) | |
| Grade 3 | 16 (28.6%) | |
| CD163 cell infiltration | Grade 0 | 16 (28.6%) |
| Grade 1 | 17 (30.4%) | |
| Grade 2 | 12 (21.4%) | |
| Grade 3 | 11 (19.6%) | |
| MMP-11 expression | Grade 0 | 17 (30.4%) |
| Grade 1 | 20 (35.7%) | |
| Grade 2 | 12 (21.4%) | |
| Grade 3 | 7 (12.5%) | |
| IL-6 expression | Grade 0 | 19 (33.9%) |
| Grade 1 | 18 (32.1%) | |
| Grade 2 | 14 (25.0%) | |
| Grade 3 | 5 (8.9%) | |
| Adjuvant chemotherapy | No | 17 (30.4%) |
| Yes | 39 (69.6%) | |
| Follow-up duration (months) | Median 41.0 (range, 0.6–102.0) | |
| Event | Yes (recurrence and/or death) | 25 (44.6%) |
| No | 31 (55.4%) | |
IL-6, interleukin-6; MMP-11, matrix metalloproteinase-11.
Statistical significance (p-value) of comparisons of textural features of primary gastric cancer on FDG PET/CT according to the histopathological results.
| Textural Features | Histopathological Classification * | Lauren Classification † | pT Stage * | pN Stage † | CD4 Cell Infiltration * | CD8 Cell Infiltration * | CD163 Cell Infiltration * | MMP-11 Expression * | IL-6 |
|---|---|---|---|---|---|---|---|---|---|
| Conventional parameters | |||||||||
| Maximum SUV | 0.032 | 0.168 | 0.624 | 0.014 | 0.088 | 0.010 | 0.062 | 0.221 | 0.644 |
| MTV | 0.908 | 0.826 | 0.002 | 0.017 | 0.585 | 0.109 | 0.933 | 0.932 | 0.919 |
| TLG | 0.602 | 0.703 | 0.024 | 0.017 | 0.432 | 0.021 | 0.668 | 0.977 | 0.788 |
| First-order textural features | |||||||||
| SUV histogram kurtosis | 0.322 | 0.077 | 0.202 | 0.079 | 0.328 | 0.682 | 0.008 | 0.375 | 0.542 |
| SUV histogram skewness | 0.081 | 0.032 | 0.665 | 0.136 | 0.595 | 0.408 | 0.007 | 0.507 | 0.525 |
| SUV histogram energy | 0.167 | 0.087 | 0.407 | 0.038 | 0.253 | 0.026 | 0.098 | 0.171 | 0.381 |
| SUV histogram entropy | 0.047 | 0.122 | 0.593 | 0.024 | 0.313 | 0.019 | 0.062 | 0.193 | 0.571 |
| Second-order textural features | |||||||||
| GLCM contrast | 0.323 | 0.092 | 0.843 | 0.035 | 0.372 | 0.077 | 0.249 | 0.022 | 0.229 |
| GLCM correlation | 0.036 | 0.582 | 0.061 | 0.016 | 0.186 | 0.012 | 0.090 | 0.854 | 0.351 |
| GLCM dissimilarity | 0.084 | 0.015 | 0.881 | 0.092 | 0.691 | 0.069 | 0.480 | 0.069 | 0.528 |
| GLCM energy | 0.061 | 0.016 | 0.594 | 0.018 | 0.333 | 0.022 | 0.136 | 0.135 | 0.405 |
| GLCM entropy | 0.224 | 0.122 | 0.673 | 0.012 | 0.268 | 0.036 | 0.048 | 0.120 | 0.322 |
| GLCM homogeneity | 0.076 | 0.080 | 0.825 | 0.044 | 0.323 | 0.051 | 0.062 | 0.067 | 0.521 |
GLCM, gray-level co-occurrence matrix; IL-6, interleukin-6; MMP-11, matrix metalloproteinase-11; MTV, metabolic tumor volume; SUV, standardized uptake value; TLG, total lesion glycolysis. * Results of the Kruskal–Wallis test. † Results of the Mann–Whitney test.
Univariate analysis for predicting RFS.
| Variables | Hazard Ratio | ||
|---|---|---|---|
| Age | 0.796 | 1.11 (0.50–2.45) | |
| Sex | 0.275 | 1.73 (0.65–4.60) | |
| Histopathological classification | Poorly-differentiated adenocarcinoma | 0.464 | 1.39 (0.58–3.31) |
| Signet ring cell carcinoma | 0.933 | 0.95 (0.27–3.30) | |
| Lauren classification | 0.751 | 0.97 (0.44–2.17) | |
| pT stage | T3 stage | 0.083 | 6.29 (0.79–50.30) |
| T4 stage | 0.005 | 18.69 (2.46–141.80) | |
| pN stage | 0.005 | 8.11 (1.91–34.56) | |
| TNM stage | <0.001 | 6.68 (2.28–19.63) | |
| Adjuvant treatment (Yes vs. No) | 0.071 | 2.79 (0.92–8.12) | |
| Conventional parameter | Maximum SUV | 0.019 | 2.59 (1.17–5.70) |
| MTV | 0.002 | 3.68 (1.65–8.23) | |
| TLG | 0.002 | 3.77 (1.66–8.55) | |
| First-order textural feature | SUV histogram kurtosis | 0.117 | 1.50 (0.51–3.89) |
| SUV histogram skewness | 0.117 | 1.90 (0.85–4.25) | |
| SUV histogram energy | 0.007 | 0.33 (0.15–0.74) | |
| SUV histogram entropy | 0.006 | 3.10 (1.39–6.93) | |
| Second-order textural feature | GLCM contrast | <0.001 | 3.86 (1.73–8.59) |
| GLCM correlation | 0.178 | 1.83 (0.76–4.39) | |
| GLCM dissimilarity | 0.009 | 2.89 (1.30–6.41) | |
| GLCM energy | 0.034 | 0.42 (0.19–0.94) | |
| GLCM entropy | 0.007 | 3.08 (1.37–6.94) | |
| GLCM homogeneity | 0.036 | 0.43 (0.20–0.95) | |
GLCM, gray-level co-occurrence matrix; MTV, metabolic tumor volume; RFS, recurrence-free survival; SUV, standardized uptake value; TLG, total lesion glycolysis. * Results of the Cox proportional hazards regression analysis.
Multivariate analysis of textural features for predicting RFS after adjustment for age, sex, and TNM stage.
| Variables | Hazard Ratio | ||
|---|---|---|---|
| Convention parameter | Maximum SUV | 0.029 | 2.99 (1.12–7.99) |
| MTV | 0.072 | 2.20 (0.91–5.50) | |
| TLG | 0.078 | 2.36 (0.91–6.14) | |
| First-order textural feature | SUV histogram energy | 0.086 | 0.49 (0.22–1.11) |
| SUV histogram entropy | 0.033 | 3.04 (1.09–8.45) | |
| Second-order textural feature | GLCM contrast | 0.006 | 3.88 (1.47–10.22) |
| GLCM dissimilarity | 0.007 | 4.14 (1.49–11.53) | |
| GLCM energy | 0.167 | 0.50 (0.19–1.33) | |
| GLCM entropy | 0.020 | 3.19 (1.20–8.47) | |
| GLCM homogeneity | 0.046 | 0.37 (0.14–0.98) | |
GLCM, gray-level co-occurrence matrix; MTV, metabolic tumor volume; RFS, recurrence-free survival; SUV, standardized uptake value; TLG, total lesion glycolysis. * Results of the Cox proportional hazards regression analysis.
Figure 3Cumulative RFS curves according to the cut-off values of maximum SUV (a), SUV histogram entropy (b), GLCM contrast (c), GLCM dissimilarity (d), GLCM entropy (e), and GLCM homogeneity (f). p-values are the results of the log-rank test.